Shandong Xinhua Pharmaceutical Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Shandong Xinhua Pharmaceutical.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	10.8%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Shandong Xinhua Pharmaceutical n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SEHK:719 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2024	8,337	449	169	443	N/A
6/30/2024	8,161	492	20	323	N/A
3/31/2024	7,936	487	166	487	N/A
12/31/2023	8,101	497	-60	265	N/A
9/30/2023	8,547	510	349	601	N/A
6/30/2023	8,511	486	337	584	N/A
3/31/2023	8,311	454	353	592	N/A
1/1/2023	7,503	411	513	758	N/A
9/30/2022	7,073	357	5	263	N/A
6/30/2022	6,673	343	32	289	N/A
3/31/2022	6,623	357	-107	152	N/A
12/31/2021	6,560	349	10	259	N/A
9/30/2021	6,307	364	-19	248	N/A
6/30/2021	6,271	353	107	385	N/A
3/31/2021	6,068	339	123	405	N/A
12/31/2020	6,006	325	140	420	N/A
9/30/2020	5,814	305	208	453	N/A
6/30/2020	5,769	323	75	392	N/A
3/31/2020	5,682	310	69	399	N/A
12/31/2019	5,606	300	-18	348	N/A
9/30/2019	5,716	303	3	480	N/A
6/30/2019	5,680	281	-85	344	N/A
3/31/2019	5,457	264	-26	382	N/A
12/31/2018	5,245	255	-65	324	N/A
9/30/2018	5,023	229	60	339	N/A
6/30/2018	4,800	226	N/A	517	N/A
3/31/2018	4,638	226	N/A	332	N/A
12/31/2017	4,516	210	N/A	390	N/A
9/30/2017	4,491	207	N/A	391	N/A
6/30/2017	4,420	183	N/A	365	N/A
3/31/2017	4,306	154	N/A	446	N/A
12/31/2016	4,015	122	N/A	439	N/A
9/30/2016	3,800	110	N/A	388	N/A
6/30/2016	3,647	103	N/A	359	N/A
3/31/2016	3,602	89	N/A	414	N/A
12/31/2015	3,597	83	N/A	349	N/A
9/30/2015	3,604	64	N/A	304	N/A
6/30/2015	3,678	36	N/A	284	N/A
3/31/2015	3,653	62	N/A	266	N/A
12/31/2014	3,590	51	N/A	346	N/A
9/30/2014	3,769	52	N/A	N/A	N/A
6/30/2014	3,635	74	N/A	235	N/A
3/31/2014	3,588	50	N/A	290	N/A
12/31/2013	3,391	39	N/A	105	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 719 est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 719 devraient croître plus rapidement que le marché Hong Kong

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 719 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de 719 devraient croître plus rapidement que le marché Hong Kong.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de 719 devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 719 devrait être élevé dans 3 ans

Shandong Xinhua Pharmaceutical Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application

Investor sentiment improves as stock rises 16%

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application

Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs

Upcoming dividend of HK$0.027 per share

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Dividend of HK$0.27 announced

Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 21% overvalued

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.6% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Now 21% undervalued after recent price drop

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020)

Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd.